Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Lara Goldstein

Psychedelics Company's $60M Series A For Startup To Develop Treatment For Mental Health Disorders

Biotech company focused on creating next-gen serotonergic neuroplastogen psychedelic compounds to treat severe neuropsychiatric and neurological conditions Lusaris Therapeutics launched with a $60 million Series A financing. 

The round was led by the company’s incubator, RA Capital Management, together with important healthcare investors including Venrock Healthcare Capital Partners, Deep Track Capital and Boxer Capital.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.